Developing new vaccines for infectious diseases and bioterrorism
Official title: Vaccine Manufacturing and Characterization Services
Funded at Idt Biologika Gmbh · NIH-9746965 · Data updated 2026-11-12
This study is all about creating new vaccines to help protect people from infectious diseases, including those that could come from bioterrorism or drug-resistant germs, so that patients can have better options for staying healthy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Idt Biologika Gmbh NIH-funded |
| Lab location | 1 site (Dessau-Rosslau, Germany) |
| Project start | May 15, 2018 |
| Project end | May 14, 2028 |
| Funding year | 2018 |
| Award (this year) | $88,990 |
| NIH project number | 272201800011I-0-27200001-1 |
| Project ID | NIH-9746965 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals at risk for emerging infectious diseases or those affected by drug-resistant pathogens.
✕Less likely to help
Patients with established vaccines for their conditions or those not at risk for infectious diseases may not receive benefit from this research.
What this research studies
This research focuses on the manufacturing and characterization of vaccines and biologics aimed at combating infectious diseases, including those that may arise from bioterrorism and drug-resistant pathogens. It involves a comprehensive approach that includes product development planning, optimization, and compliance with regulatory standards for clinical studies. Patients may benefit from the development of new vaccines that are specifically designed to address emerging health threats. The research also includes the production of vaccine components and delivery systems.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines that protect against serious infectious diseases and bioterrorism threats.
How similar studies have gone: Previous research has shown success in developing vaccines for infectious diseases, indicating that this approach has potential for significant advancements.
Where this research is happening
-
Idt Biologika Gmbh
Dessau-Rosslau, Germany Active
Researchers
- Principal investigator: Neubert, Andreas — Idt Biologika Gmbh
- Study coordinator: Neubert, Andreas
Related research
Other NIH-funded projects on the same topics.
-
Creating master cell banks for new SARS-CoV-2 vaccines
This study is working on creating special cell banks to help make better vaccines for COVID-19, which could lead to more effective options for patients in the future.
-
Creating materials for testing new influenza vaccines
This study is working on creating and improving materials for new flu vaccines, which could help keep you and others safer from the flu and similar illnesses.
-
Creating master cell banks for new SARS-CoV-2 vaccines
This study is working on creating special cell banks to help make better vaccines for COVID-19, so that patients can have more effective protection against the virus and its variants.
-
Creating vaccines and biologics to combat infectious diseases
This study is working on creating new vaccines to help protect people from infections like those caused by E. coli, so that patients can have better options for staying healthy and safe from serious diseases.
-
Developing a vaccine for Staphylococcus aureus
This study is working on creating a new vaccine to help protect people from Staphylococcus aureus infections, which can be tough to treat because the bacteria resist many antibiotics, and it aims to make this vaccine safe and effective for future use.
-
Developing a vaccine using Vero cells for respiratory syncytial virus (RSV)
This study is working on making a safe and effective vaccine to protect babies and young kids from respiratory syncytial virus (RSV), which often causes breathing problems, by improving how the vaccine is produced.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.